As of June 30, 2026, Genertec Universal Medical Group Company Limited carries a market capitalization of 1.02B, placing it among publicly traded companies globally. Its enterprise value stands at 7.61B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.02B |
| Enterprise Value | 7.61B |
Genertec Universal Medical Group Company Limited's next confirmed earnings release is scheduled for March 31, 2027.
| Earnings Date | 3/31/2027 |
As of June 30, 2026, Genertec Universal Medical Group Company Limited has 2.01B shares outstanding.
| Shares Outstanding | 2.01B |
These figures are as of June 30, 2026.
| PB Ratio | 0.36 |
| P/TBV Ratio | 0.38 |
As of June 30, 2026, Genertec Universal Medical Group Company Limited maintains a current ratio of 1.24, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 1.24 |
| Quick Ratio | 0.08 |
| Debt / Equity | 191.82 |
These figures cover the twelve months ended June 30, 2026.
| Employee Count | 23,791.00 |
As of the close on November 17, 2026, Genertec Universal Medical Group Company Limited's stock has declined approximately 24.29% over the past 52 weeks. The 50-day moving average sits at 0.51, while the 200-day moving average is 0.56.
| 52-Week Price Change | -24.29% |
| 50-Day Moving Average | 0.51 |
| 200-Day Moving Average | 0.56 |
As of June 30, 2026, Genertec Universal Medical Group Company Limited holds 319.67M in cash and equivalents against 6.38B in total debt, resulting in a net debt position of 5.98B. Total book value stands at 2.79B, with working capital of 1.01B providing operational flexibility.
| Cash & Cash Equivalents | 319.67M |
| Total Debt | 6.38B |
| Net Debt | 5.98B |
| Equity (Book Value) | 2.79B |
| Book Value Per Share | 1.39 |
| Working Capital | 1.01B |
Already premium?